Personalis & Natera enter partnership to boost personalized oncology
Category: #health  By Pankaj Singh  Date: 2021-02-19
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Personalis & Natera enter partnership to boost personalized oncology

Personalis, Inc., a cancer genomics company, has recently entered a partnership deal with Natera, Inc., a leading provider of cell-free DNA testing, to advance personalized oncology. Under this agreement, the NeXT tumor profiling & diagnostic products of Personalis will be combined with the personalized ctDNA platform of Natera, Signatera™, to monitor treatment as well as assess MRDs (molecular residual diseases).

Natera emphasizes on revolutionizing disease management worldwide by lending a strong focus on women’s health, organ health, and oncology. The company delivers proprietary genetic testing services to the genetic laboratories, oncologists, transplant physicians, obstetricians, and cancer researchers such as the biopharmaceutical companies via its cloud-based software platform. On the other hand, Personalis supports the development of next-gen therapies by offering comprehensive molecular data of patients’ cancer and immune response.

As per the non-exclusive agreement, the genetic testing company will validate the design of Signatera™, a personalized ctDNA assays, by using Personalis’ matched tumor & normal exome sequence data. The company will also be responsible for its commercialization. The deal covers MRD testing for use in both research and clinical settings.

According to the General Manager of Oncology of Natera, Solomon Moshkevich, the recent partnership deal will enhance the vision of the company in boosting its Signatera™ business as a personalized monitoring & MRD platform. This can be rapidly scaled and integrated with the exome-scale tissue sequencing assays of high-quality, like Personalis’ NeXT, across the globe. The company has shown excitement towards partnering with the team at Personalis as well as helping potential customers gain access to Signatera™.

Personalis’ Chief Scientific Officer, Richard Chen, has reportedly cited that the NeXT Platform™ will complement Signatera™ by delivering advanced tumor analysis with high coverage across all the 20,000 genes. The company is thrilled to partner with Natera on the new sensitive tumor-informed approach to increase the detection of molecular residual disease in cancer.

Source credit:

https://www.businesswire.com/news/home/20210217005333/en/Natera-and-Personalis-Partner-for-Personalized-Monitoring-in-Oncology



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

BPOC joins hands with SPCP to expand access to healthcare services

BPOC joins hands with SPCP to expand access to healthcare services

By Pankaj Singh

Healthcare-focused private equity company BPOC has recently inked a collaboration with Dr. Thomas Bat, in order to form a regionally focused primary case MSO (management services organization). SPCP (Southeast Primary ...

MercadoLibre planning to double workforce amid e-commerce boom

MercadoLibre planning to double workforce amid e-commerce boom

By Pankaj Singh

MercadoLibre Inc., an Argentinian e-commerce firm, has reportedly planned to bump up their workforce this year. The company has also invested USD 1.1 billion for expanding their services and warehouse space in Mexico, ...

Vesta Healthcare raises $65M for home healthcare transformation

Vesta Healthcare raises $65M for home healthcare transformation

By Pankaj Singh

Leading digital health and 24/7 clinical provider, Vesta Healthcare, has reportedly secured nearly $65M in a financing led by Deerfield Management Company. The event also saw participation from existing investors, such...